Skip header and navigation

Narrow By

   MORE

2 records – page 1 of 1.

5-Aminosalicylate (5-ASA) for inflammatory bowel disease (IBD)

https://libcat.nshealth.ca/en/permalink/chpams35397
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program. Halifax, NS: Nova Scotia Health Authority , 2022.
Pamphlet Number
1483
Available Online
View Pamphlet
5-aminosalicylate (5-ASA) is a medication often used to treat inflammatory bowel disease (IBD). It helps to controll active ulcerative colitis, or Crohn’s colitis and keep mild to moderate ulcerative colitis in remission (period of recovery). Topics include: what does 5-ASA do, which 5-ASA you should take, how to take 5-ASA, what other medications you can take, and how 5-ASA will help. The pamphlet also describes side effects and how long you will need to take 5-ASA.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2022
Format
Pamphlet
Language
English
Physical Description
1 electronic document (5 p.) : digital, PDF file
Subjects (MeSH)
Inflammatory Bowel Diseases - drug therapy
Crohn Disease - drug therapy
Colitis - drug therapy
Subjects (LCSH)
Inflammatory bowel diseases
Crohn's disease
Colitis
Abstract
5-aminosalicylate (5-ASA) is a medication often used to treat inflammatory bowel disease (IBD). It helps to controll active ulcerative colitis, or Crohn’s colitis and keep mild to moderate ulcerative colitis in remission (period of recovery). Topics include: what does 5-ASA do, which 5-ASA you should take, how to take 5-ASA, what other medications you can take, and how 5-ASA will help. The pamphlet also describes side effects and how long you will need to take 5-ASA.
Notes
Previous title: 5-Aminosalicylate (5-ASA)
Responsibility
Prepared by: Nova Scotia Collaborative IBD Program
Pamphlet Number
1483
Less detail

Infliximab therapy for inflammatory bowel disease (IBD)

https://libcat.nshealth.ca/en/permalink/chpams34944
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program. Halifax, NS: Nova Scotia Health Authority , 2022.
Pamphlet Number
1140
Available Online
View Pamphlet
Your health care provider feels that treatment with infliximab may help you to manage your inflammatory bowel disease (IBD). This pamphlet describes what infliximab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2022
Format
Pamphlet
Language
English
Physical Description
1 electronic document (12 p.) : digital, PDF file
Subjects (MeSH)
Inflammatory Bowel Diseases - drug therapy
Infliximab
Subjects (LCSH)
Inflammatory bowel diseases
Infliximab
Abstract
Your health care provider feels that treatment with infliximab may help you to manage your inflammatory bowel disease (IBD). This pamphlet describes what infliximab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
Notes
Previous title: Infliximab (Remicade) therapy
Responsibility
Prepared by: Nova Scotia Collaborative IBD Program
Pamphlet Number
1140
Less detail